Japanese drug firm Astellas seeks Dx companions with 'precision medicine' strategy
This article was originally published in Clinica
By focusing its latest "R&D day" solely on oncology, Japanese drug company Astellas intended to send out a clear message that it is serious about building its presence in the field, outlining an expanding development pipeline that is particularly well stocked at the Phase I/II stage.
You may also be interested in...
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.